Synopsis: Markets regulator SEBI has issued an ex-parte interim order barring Elitecon International Limited, its promoter-MD Vipin Sharma, and four other entities from dealing in securities, while ordering the impoundment of alleged unlawful gains of Rs. 51.26 crore.
A regulatory enforcement order from SEBI has put a BSE-listed tobacco company in focus after the regulator alleged that its promoters devised a scheme to artificially inflate the stock price through misleading public disclosures, then offloaded their holdings to retail investors at elevated levels. The order is interim and ex-parte in nature and the allegations remain subject to adjudication. No final determination of guilt has been made.
With a market capitalization of approx Rs. 7,733 crore, the shares of Elitecon International Limited shares closed at Rs. 48.38 per share on March 30, 2026, down 4.8 percent from its previous closing price of Rs. 50.82.
SEBI’s Interim Order: What It Does
SEBI’s ex-parte interim order directs four immediate actions against Elitecon International and five named individuals.
- First, a securities ban: the company, its promoter and managing director Vipin Sharma, and four other entities: Pawan Kumar Ray, Gaurav Tyagi, Prabhakar Kumar, and Sujit Chaturvedi; have been restrained from buying, selling, or dealing in securities until further notice.
- Second, an impoundment: alleged unlawful gains totalling Rs. 51.26 crore have been ordered impounded.
- Third, an asset freeze: bank accounts and demat accounts of all named entities have been frozen to the extent of the impounded amount.
- Fourth, a forensic audit: SEBI has directed appointment of a forensic auditor to examine the company’s books of accounts and affairs in detail.
The Alleged Scheme
SEBI’s order, as reported, identifies three overlapping mechanisms through which the alleged manipulation is said to have operated. The first involves information asymmetry: the regulator found that the company suppressed material adverse information including GST-related proceedings and an FDA Nashik factory inspection in which inventory and a packing machine were reportedly taken while simultaneously making “rosy” and misleading disclosures designed to sustain positive market sentiment.
The second involves coordinated price inflation: SEBI alleges the entities consolidated shareholding, generated artificial buying interest through misleading announcements, and drove up the price to enable a structured exit to retail investors at elevated levels.
The third, and potentially the most damaging for the company’s credibility as a listed entity, involves alleged financial misrepresentation: SEBI noted that net sales surged 538 percent year-on-year in Q2 FY26 (September 2025 quarter); a spike the regulator characterised as showing “extreme and unexplained growth” that appeared prima facie to be misrepresented. The stock’s trajectory is broadly consistent with this characterisation: it climbed from lows near Rs. 30 to an adjusted 52-week high of Rs. 402 before collapsing, declining approximately 72 percent over the six months to March 2026.
Prior Red Flags on the Public Record
Several indicators that SEBI’s order now contextualises were already visible in the company’s public filing trail. The FDA Nashik inspection which the company had disclosed to exchanges, stating operations remained unaffected, involved the seizure of inventory and a packing machine.
Separately, Elitecon disclosed legal proceedings with Advik Capital Ltd over alleged forged loan documents, with the next hearing scheduled. BSE had imposed a fine of Rs. 1,12,100 on the company for late submission of unaudited results for Q3 FY26. The stock had also been placed under the Additional Surveillance Measure framework by the exchanges.
Business Overview
Elitecon International Limited, formerly known as Kashiram Jain and Company Limited, was incorporated on December 15, 1987, and was transformed into its current avatar in July 2019. The company is engaged in manufacturing and trading of cigarettes, smoking mixture, sheesha, and other tobacco-allied products for both domestic and overseas markets, with export presence in the UAE, Singapore, Hong Kong, and parts of Europe.
In Q3 FY26, the company reported standalone net profit of Rs. 104 crore on net sales of Rs. 1,741 crore. These figures are now subject to forensic examination as directed by SEBI.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post SEBI Bans Elitecon International Promoters from Buying and Selling Shares Over Alleged Price Manipulation appeared first on Trade Brains.